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There is no consensus guideline concerning the management of chronic hepatitis C patients during chemotherapy, and
immunosuppression. However, there are some suggestions in literature that hepatitis C viral load increases during chemotherapy
and there is a risk of rebound immunity against hepatitis C after discontinuation of immunosuppression with a consequent
liver injury. A close monitoring of liver function of these patients is prudent during treatment of haematological malignancy.
Antiviral treatment is deferred after the completion of chemotherapy and recovery of patients’ immunity to minimize the toxicity
of treatment. A combination of pegylated interferon and ribavirin is the standard therapy in hepatitis C infected haematological
patients.
1.Introduction
It is well known that reactivation of hepatitis B is a
potential lethal complication of chemotherapy and pro-
phylactic antiviral drugs are prudent during treatment of
haematological malignancies. However, on the contrary, it
is not certain how chronic hepatitis C infection would
aﬀect the outcome of haematological malignancies and bone
marrow transplantation patients. There are case reports of
severe ﬂare up of chronic hepatitis C in patients undergoing
chemotherapy [1, 2] but case series review found such
complications uncommon [3]. On the other hand, long-
term survivors of bone marrow transplantation recipients
are more prone to the complications of hepatitis C infection
[4] and treatment in this group of patients seems warranted.
However, there is scanty data on management of chronic
hepatitis C in haematology patients.
Hepatitis C is associated with development of haemato-
logical diseases ranging from immune thrombocytopenia to
lymphoma. The underlying pathogenesis and its impact on
treatment are discussed.
2.HepatitisC
There are six major genotypes of hepatitis C and more than
50 subtypes. Genotype 1b is the most common subtype
worldwide. About 170 million people have chronic hepatitis
and the estimated annual incidence of new case of hepatitis
Cis3t o4millio ns[5].Inastudy inEurope,theapproximate
prevalence of chronic hepatitis C among bone marrow
transplantation recipients is 6% [6].
Sixty to eighty percent of patients develop chronic
hepatitis C after acute infection. About twenty percent of
these patients will be complicated by cirrhosis in twenty to
thirty years, and some of them may develop hepatocellular
carcinoma [5, 7]. It is believed that successful control of viral
replication by eﬀective antiviral treatment would prevent
such complications in these patients [8, 9].
3.StatusofHepatitisCduringChemotherapy
andImmunosuppression
The level of hepatitis C viral RNA in blood has been shown
to increase during chemotherapy and immunosuppression.
At the same time, for those with pre-existing liver dys-
function, the transaminase levels often normalize during
immunosuppression. Upon the withdrawal of chemotherapy
or immunosuppressants, the hepatitis C viral RNA decreases
with a concomitant rise in transaminase levels. In a study
of ten chronic hepatitis C patients, the alanine transam-
inase level decreased in eight patients while all of them2 Hepatitis Research and Treatment
demonstrated a rise in hepatitis C RNA during a seven-
week course of prednisone whereas there was a rebound of
alaninetransaminaseuponthewithdrawalofsteroidinseven
of them [10]. None of these patients developed fulminant
hepatitis. Similarly, in another study of lymphoma patients
who received rituximab with combination chemotherapy,
the hepatitis C RNA increased during chemotherapy and
declined after completion of treatment. The use of rituximab
in patients without hepatitis seldom leads to hepatotoxicity.
However, in this cohort, one patient developed signiﬁcant
hepatotoxicity during rituximab chemotherapy [11].
This ﬂuctuation in hepatitis C viral load and liver
enzymesduringandafterchemotherapyorimmunosuppres-
sion is explained by the suppression of immunity during
chemotherapy and a rebound of reaction towards hepatitis
C upon its withdrawal.
However, despite the above observations, the clinical
impact of chronic hepatitis C infection on patients under-
going bone marrow transplantation or chemotherapy is not
well characterized. In a study in United States, among thirty
three chronic hepatitis C patients, only eighteen of them
(55%) developed mild to modest elevation of liver enzymes
during chemotherapy [3]. None of them developed severe
ﬂare up that required cessation of chemotherapy. On the
contrary, a study in Europe reported that up to 65% of
the patients with chronic hepatitis C infection developed
signiﬁcant hepatotoxicity during chemotherapy [12]. This
high incidence of hepatotoxicity led to interruptions in
chemotherapy and jeopardized the clinical outcome of these
patients. In another study of 132 patients, ﬁve patients
had to discontinue chemotherapy because of severe hepatic
dysfunction during treatment [13]. In a recently published
review of 160 chronic hepatitis C patients with non-
Hodgkin lymphoma, twenty-four (15%) of them developed
signiﬁcant liver toxicity during chemotherapy [14]. The
overall survival of chronic hepatitis C patients is also shown
to be signiﬁcantly worse than those without hepaitits C
infection. At a median followup of two years of patients
diagnosed with diﬀuse large B cell lymphoma in Groupe
d’Etude des Lymphomes de l’Adulte (GELA) programs, the
overall survival was 56% among chronic hepatitis C patients
versus 80% in those without (P = .02) [12].
The reported incidence of hepatotoxicity in chronic
hepatitis C patients undergoing chemotherapy varies greatly
among these studies. In addition, because of the bleeding
tendency commonly seen in haematology patients, all these
studies only monitored liver enzymes and hepatitis C RNA
level but none of them was based on histological evidence.
Therefore, there is yet concrete data on the eﬀect of chronic
hepatitis C infection in patients receiving chemotherapy and
more studies are needed in this aspect.
4.HepatitisCinHematopoieticStem
CellTransplantation
Hepatitis C infection is associated with an increased risk of
veno-occlusive disease (VOD) and graft-versus-host disease
(GVHD) of liver. The reported incidence of VOD was 14%
among those with chronic hepatitis C infection while it
was only 8% in transplant recipients who were negative
for hepatitis C. The chronic inﬂammation in hepatitis C-
infected liver causes endothelial changes in the hepatic
sinusoids and this may predispose the patients to VOD
during bone marrow transplant [15].
Although signiﬁcant liver dysfunction during or imme-
diately posttransplant is uncommon, bone marrow trans-
plantation recipients with chronic hepatitis C infection have
a signiﬁcantly worse long-term outcome. The estimated
incidence of cirrhosis at twenty years post bone marrow
transplantation is 24% in those with chronic hepatitis C
[16]. Moreover, there is evidence that the annual ﬁbrosis
progressionrateissigniﬁcantlyhigherinposttransplantation
patients than those chronic hepatitis C patients without
transplantation [4]. In fact, chronic hepatitis C infection
ranked the third as a cause of late mortality, after infections
and GVHD in posttransplant patients [16]. Once they
developed cirrhosis, their survival outcomes are markedly
compromised.
5. Treatment of HepatitisC in
HaematologicalPatients
The current standard of treatment of chronic hepatitis
C infection is a combination of pegylated interferon and
ribavirin. There is currently no speciﬁc guideline for treat-
ment of the infection in haematological malignancy patients.
In these patients, including bone marrow transplantation
recipients, hepatitis C treatment is deferred until patients’
immunity and bone marrow recover. In particular, for
allogeneic stem cell transplantation patients, hepatitis C
treatment should be withheld until all immunosuppressants
are tailed oﬀ and GVHD is completely resolved. Interferon
is known to suppress bone marrow hematopoiesis and this
would aggravate the cytopenia frequently seen in postbone
marrow transplantation patients. Moreover, it is reported
that the use of interferon in allogeneic bone marrow
transplantation patients might trigger GVHD, and its use in
stem cell recipients should be cautious [17]. Ribavirin may
suppress erythropoiesis and this may aggravate the degree
of anemia in hematology patients. The use of erythropoietin
however, is shown to reduce the transfusion requirement of
these patients.
Combination therapy of pegylated interferon and rib-
avirin is shown to produce a sustained virological response,
that is, undetectable hepatitis C RNA six months oﬀ
therapy, in 20% of chronic hepatitis C patients after bone
marrow transplantation. This response rate is compared
unfavourably with that reported for the general population.
Moreover, 30% of the studied patients did not receive this
treatment because of the presence of contraindications [18].
The poor tolerability among hematology patients and their
inferior treatment outcome warrant more research in this
particular group of patients.
6.HepatitisCandAutoimmuneCytopenia
Chronic hepatitis C infection is associated with thrombo-
cytopenia, and the cause is multifactorial in most patients.Hepatitis Research and Treatment 3
There are various possible explanations, which include
increased sequestration and destruction of platelets in
patients with hypersplenism, reduced thrombopoiesis as a
result of decreased production of endogenous thrombopoi-
etin by diseased liver, direct marrow suppression by hepatitis
C virus as well as dysregulation of immunity leading to
autoimmune thrombocytopenia. One study demonstrated
the presence of increased level of antiplatelet glycoproteins
in serum of chronic hepatitis C infected patients with
thrombocytopenia [19]. A signiﬁcant proportion of these
patients responded to standard immune thrombocytopenia
therapy such as steroids and intravenous immunoglob-
ulin. In two of the studied patients, the platelet count
normalized after receiving pegylated interferon plus rib-
avirin therapy. The rise of platelet count in one of these
patients coincided with the disappearance of hepatitis C
RNA in blood [19]. Although it is well known that
interferon causes cytopenia, its administration in hepati-
tis C infected patients with cytopenia is not necessarily
contraindicated but should be evaluated on an individual
basis.
7. Hepatitis C in Lymphomagenesis
It is well known that hepatitis C is a lymphotropic virus
and is able to infect mononuclear cells in peripheral blood.
Chronic hepatitis C infection is associated with various lym-
phoproliferative disorders and the most commonly reported
association is mixed essential cryoglobulinemia. More than
95% of patients with mixed cryoglobulinemia have evidence
of exposure to hepatitis C virus [20, 21].
B-cell clonality and t(14;18) translocation are both
prevalent in the peripheral blood mononuclear cells of
hepatitis C infected patients [22]. It has been shown that
chronic hepatitis C infection is signiﬁcantly associated with
the development of non-Hodgkin lymphoma. The reported
odds ratio ranged from 2 to 4, with the risk being more
evident in area with a higher prevalence of hepatitis C
infection [23] .T h em o s tc o m m o n l yr e p o r t e ds u b t y p e so f
non-Hodgkin lymphoma in chronic hepatitis C infected
patients are marginal zone lymphoma and lymphoplasma-
cytic lymphoma. There are also reports on an increased
prevalence of high grade B-cell lymphoma in hepatitis C
infected patients but majority of them were arising from an
underlying low-grade lymphoma.
It is found that CD81 is a hepatitis C coreceptor and
it is expressed in B lymphocytes [24]. The engagement of
CD81, which is part of the CD81/CD19/CD21 membrane
complex, activate B lymphocytes and subsequently lead
to their proliferation. As a result, this chronic antigenic
stimulation may predispose to the development of B-cell
lymphoproliferative disorders [25]. On the other hand, there
are suggestions that chronic hepatitis C infection induces
point mutations in both immunoglobulin and nonim-
munoglobulin genes of infected B lymphocytes [26, 27]. It
is, however, still controversial whether hepatitis C virus has a
direct oncogenic eﬀect. More studies are warranted before a
deﬁnitive conclusion can be made.
8.RoleofAntiviralTreatmentinHepatitis
C-AssociatedLymphoproliferative Diseases
As hepatitis C plays an important role in lymphomagenesis,
it is postulated that eradication of virus may produce a
response in its haematological manifestation as well. In a
review of eighteen hepatitis C infected patients with indolent
B-cell lymphoma, an overall response rate of the lymphoma
after antiviral treatment alone was 63% and 80%, respec-
tively, in the group receiving interferon plus ribavirin and
pegylated interferon plus ribavirin, respectively [28]. There
was,however,persistentpresenceofcryoglobulininmajority
of the cases despite the absence of detectable tumour. In
another study of nine hepatitis C infected patients with
splenic marginal zone lymphoma, seven of them had sus-
tained virological response after antiviral treatment (which
consisted of interferon as ﬁrst line therapy with ribavirin
added if unsatisfactory response). All seven patients had
a concomitant haematological response with a decrease in
splenic size and disappearance of villous lymphocytes from
peripheral blood [28]. In the remaining two patients who
had persistent detectable hepatitis C RNA in blood, there
was no signiﬁcant clinical haematological response. The
immunoglobulin gene rearrangement observed at diagnosis
in these patients was still detectable in patients achieving a
completeclinicalremission.Althoughantiviraltreatmenthas
a therapeutic role in the treatment of hepatitis C-associated
lymphoproliferative diseases, most of the patients still have
detectable residual diseases by molecular methods. Antiviral
t h e r a p ya l o n ei su n a b l et oa c h i e v eac o m p l e t er e m i s s i o no f
their haematological diseases in these patients.
9. Conclusion
There are diﬀerent opinions on the risk of hepatic dys-
function during chemotherapy for haematological patients
with chronic hepatitis C infection. No consensus guidelines
concerning the management of these patients are currently
available and more studies on this issue are warranted.
The role of hepatitis C infection in lymphomagenesis
is intriguing and a better understanding may help our
management of hepatitis C-associated lymphoproliferative
diseases. Although antiviral treatment may not be able
to eradiate hepatitis C-associated lymphoma, it should
be considered as a treatment option for tumour control,
especially for those who may not be able to tolerate cytotoxic
chemotherapy.
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